Thyroid Drug & Bone Loss; GLP-1s’ Renal Benefit; Menopause Musculoskeletal Syndrome

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the Radiological Society of North America’s annual meeting.

In a phase II study, investigational maridebart cafraglutide (MariTide) yielded around 20% weight loss at 52 weeks, Amgen announced.

A meta-analysis of 11 randomized trials in type 2 diabetes showed that GLP-1 receptor agonists significantly reduced clinically important kidney events, kidney failure, and cardiovascular events. (Lancet Diabetes & Endocrinology)

The FDA is formally probing the presence and impact of per- and polyfluoroalkyl substances — endocrine-disruptors known as forever chemicals — in the nation’s seafood.

Treatment with the aromatase inhibitor anastrozole decreased the rate of bone maturation and improved height outcomes in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (Journal of Clinical Endocrinology & Metabolism)

Body aches with menopause? It could be the musculoskeletal syndrome of menopause. (New York Times)

Disparities in access to novel anti-obesity drugs could be made worse if the medications are denied to people who cannot participate in comprehensive lifestyle intervention programs due to competing demands or comorbidities, editors at JAMA Internal Medicine argued.

The food industry is grappling with a possible mass decrease in the public’s appetite for ultraprocessed foods with the increased use of GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic). (New York Times Magazine)

Metabolic syndrome was associated with an 11% increased risk of dementia in a 25-year cohort study. (Lancet Healthy Longevity)

The glucagon analog dasiglucagon (Zegalogue) significantly reduced the amount of IV glucose needed to maintain euglycemia in a small placebo-controlled trial of infants with congenital hyperinsulinism. (Journal of Clinical Endocrinology & Metabolism)

CVS Health, UnitedHealth Group, and Cigna sued the Federal Trade Commission, claiming the agency’s case against their pharmacy benefit managers over high insulin prices is unconstitutional. (CNBC)

Is Eli Lilly’s investigational weight-loss treatment retatrutide a drug or biologic? The distinction could hold significant implications for compounding capabilities. (Endpoints News)

Compared with placebo, short-term exposure to menopausal hormone therapy initiated in early postmenopause was not associated with long-term cognitive effects, according to the KEEPS-Cog trial. (PLOS Medicine)

Should people without diabetes use continuous glucose monitors? (USA Today)

Please enable JavaScript to view the comments powered by Disqus.